COVID-19疫苗接种后急性心包炎病例系列:欧洲与美国近期报告背景下的观察
该病例系列报告8例患者接种COVID-19疫苗后发生9次急性心包炎事件,涉及BNT162b2、AZD1222和mRNA-1273三种疫苗。胸痛为最常见表现,均无后遗症,2例并发心脏压塞需紧急心包减压,4例需住院。因果关系尚不能确定,但急性心包炎可能是接种后并发症。
要点
- 接种COVID-19疫苗后急性心包炎可表现为胸痛,需排除其他病因。
- 本系列中多数事件无后遗症,但可出现心脏压塞需紧急处理。
- 因果关系未确立,需进一步研究以明确该新发实体。
核心结论
- 尽管因果关系不能 firmly 确立,急性心包炎已成为COVID-19疫苗接种后可能的并发症。
- 需进一步研究以全面描述这一新发实体。
研究设计与样本
- 病例系列,报告8例患者接种COVID-19疫苗后发生的9次急性心包炎事件。
- 疫苗包括BNT162b2(6/9)、AZD1222(2/9)和mRNA-1273(1/9)。
- 所有患者因与疫苗接种时间相关的急性心包炎转诊,诊断依据ESC指南。
主要发现
- 胸痛是最常见的临床表现。
- 5次事件发生于第一剂后,4次发生于第二剂后。
- 队列平均年龄65.8 ± 10.2岁,男女比例3/5。
- 所有事件均无后遗症消退;2次事件并发心脏压塞需紧急心包减压。
- 4例需要住院。
局限性
- 因果关系不能 firmly 确立。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: COVID-19 vaccines were efficacious and safe in clinical trials. We report nine events of acute pericarditis (AP) in eight patients following COVID-19 vaccination with BNT162b2 (6/9), AZD1222 (2/9) and mRNA-1273 (1/9). METHODS: All patients were referred for AP temporally linked with COVID-19 vaccination. Chest pain was the most common clinical manifestation. Alternative etiologies were excluded upon thorough diagnostic work up. AP diagnosis was established according to ESC guidelines. FINDINGS: Five events occurred after the first vaccine dose and four after the second. The mean age in this cohort was 65.8 ± 10.2 years and the men/women ratio 3/5. All events resolved without sequelae; two events were complicated by cardiac tamponade requiring emergent pericardial decompression. Hospitalization was required in four cases. INTERPRETATION: Although causality cannot be firmly established, AP has emerged as a possible complication following COVID-19 vaccination. Further investigation is indispensable to fully characterize this new entity.
引用
- Lazaros G, Anastassopoulou C, Hatziantoniou S, et al. A case series of acute pericarditis following COVID-19 vaccination in the context of recent reports from Europe and the United States. Vaccine. 2021. PMID: 34635376. doi:10.1016/j.vaccine.2021.09.078
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。